Antiarrhythmics - From cell to clinic: Past, present, and future

Heart

Volumn 84, Issue 1, 2000, Pages 14-24

  Hancox, J C ^a   Patel, K C R ^a   Jones, J V ^b  

^a SCHOOL OF MEDICAL SCIENCES   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE; ENCAINIDE; ESMOLOL; FLECAINIDE; ION CHANNEL; LIDOCAINE; LORCAINIDE; PHENYTOIN; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL;

ACTION POTENTIAL; ARRHYTHMOGENESIS; CHANNEL GATING; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG MECHANISM; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HUMAN; PRIORITY JOURNAL; QT INTERVAL; REVIEW;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; GENE EXPRESSION; HUMANS; ION CHANNEL GATING; ION CHANNELS; ION TRANSPORT; MEMBRANE POTENTIALS;

EID: 0033946314     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Carmeliet E. Potassium channels in cardiac cells. Cardiovasc Drugs Ther 1992;6:305-12.
2. Irisawa H, Brown HF, Giles WR. Cardiac pacemaking in the sinoatrial node. Physiol Rev 1993;73:197-227.
3. Hancox JC, Mitcheson JS. Ion channel and exchange currents in single myocytes isolated from the rabbit atrioventricular node. Can J Cardiol 1997;13:1175-82.
4. Gadsby DC. The Na/K pump of cardiac cells. Annu Rev Biophys Bioeng 1984;13:373-98.
5. 2+-ATPase in the regulation of resting calcium concentration in rat ventricular myocytes. J Physiol (Lond) 1999;515:109-18.
6. Allen TJA, Noble D, Reuter H, eds. Sodium-calcium exchange. Oxford: Oxford University Press, 1989.
7. Janvier NC, Boyett MR. The role of Na-Ca exchange current in the cardiac action potential. Cardiovasc Res 1996;32:69-84.
8. Hondeghem LM, Katzung BG. Time and voltage dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim Biophys Acta 1977;472:373-98.
9. Frishman WH, Gabor R, Pepine C, et al. Heart rate reduction in the treatment of chronic stable angina pectoris: experiences with a sinus node inhibitor. Am Heart J 1996; 131:204-10.
10. Reiffen M, Eberlein W, Muller P, et al. Specific bradycardic agents. Chemistry, pharmacology and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischaemic properties. J Med Chem 1990;33:1496-504.
11. Clozel JP, Ertel EA, Ertel SI. Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens 1997; 15:S17-25.
12. Welker HA, Wiltshire H, Bullingham R. Clinical pharmacokinetics of mibefradil. Clin Pharmacokinet 1998;35:405-23.
13. Zipes DP, Mendez C. Action of manganese ions and tetrodotoxin on atrioventricular nodal transmembrane potentials in isolated rabbit hearts. Circ Res 1973;22:447-54.
14. Goy J, Fromer M. Antiarrhythmic treatment of atrioventricular tachycardias. J Cardiovasc Pharmacol 1991; 17(suppl 6):S36-40.
15. Wellens HJ, Tan SL, Bar FW, et al. Effect of verapamil studied by programmed electrical stimulation of the heart in patients with paroxysmal re-entrant supraventricular tachycardia. Br Heart J 1977;39:1058-66.
16. Shenasa M, Fromer M, Faugere G, et al. Efficacy and safety of intravenous and oral diltiazem for Wolff-Parkinson-White syndrome. Am J Cardiol 1987;59:301-6.
17. Klein HO, Pauzner H, DiSegni E, et al. The beneficial effects of verapamil in chronic atrial fibrillation. Arch Intern Med 1979;139:747-9.
18. Hille B. Local anaesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 1977;69:497-515.
19. Hondeghem LM, Matsubara T. Quinidine blocks cardiac sodium channels during opening and slow inactivation in guinea-pig papillary muscle. Br J Pharmacol 1988;93:311-18.
20. + channels by antiarrhythmic drugs: the effect of amiodarone, propafenone and diprafenone. J Membr Biol 1988;102: 105-19.
21. Grant AO, John JE, Nesterenko VV, et al. The role of inactivation in open channel block of the sodium channel: studies with inactivation-deficient mutant channels. Mol Pharmacol 1996;50:1643-50.
22. + channels. Proc Natl Acad Sci USA 1996;93:9270-5.
23. Sunami A, Fan Z, Sawanobori T, et al. Use-dependent block of Na currents by mexiletine at the single-channel level in guinea-pig ventricular myocytes. Br J Pharmacol 1993;110: 183-92.
24. Grant AO. Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination. Pace 1997;20:432-44.
25. Nitta J, Sunami A, Marumo F, et al. States and sites of actions of flecainide on guinea-pig cardiac sodium channels. Eur J Pharmacol 1992;214:191-7.
26. Wilde AAM. Proarrhythmia related to sodium channel blockade: mechanisms, monitoring, prevention and management. Cardiac Electrophysiol Rev 1998;2:136-11.
27. Cardinal R, Janse MJ, VanEeden I, et al. The effects of lidocaine on intracellular and extracellular potentials, activation and ventricular arrhythmias during acute regional ischaemia in the isolated porcine heart. Circ Res 1981;49: 792-806.
28. Lima JJ, Boudoulas H. Stereoselective effects of disopyramide enantiomers in humans. J Cardiovasc Pharmacol 1987;9:594-600.
29. Thomas SHL. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React Toxicol Rev 1994;13:77-102.
30. Virag L, Varro A, Papp JG. Effect of disopyramide on potassium currents in rabbit ventricular myocytes. Naunyn-Schmiedebergs Arch Pharmacol 1998;357:268-75.
31. Balser JR, Bennett PB, Hondeghem LM, et al. Suppression of time-dependent outward current in guinea-pig ventricular myocytes: actions of quinidine and amiodarone. Circ Res 1991;69:519-29.
32. Po SS, Wang DW, Yang ICH, et al. Modulation of HERG potassium channels by extracellular magnesium and quinidine. J Cardiovasc Pharmacol 1999;33:181-5.
33. Roden DM, Lazzara R, Rosen MR, et al, for SADS Foundation Task Force on LQTS. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps and future directions. Circulation 1996;94:1996-2012.
34. Carmeliet E. Mechanisms and control of repolarization. Eur Heart J 1993;14:3-13.
35. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990;96:195-215.
36. Sanguinetti MC, Keating MT. Role of delayed rectifier potassium channels in cardiac repolarisation and arrhythmias. News Physiol Sci 1997;12:152-7.
37. + channels and control of ventricular repolarisation in the heart. Fundam Clin Pharmacol 1993;7: 19-28.
38. Shimoni Y, Clark RB, Giles WR. Role of an inwardly rectifying potassium current in rabbit ventricular action potential. J Physiol (Lond) 1992;448:709-27.
39. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use-dependence. Circulation 1990;81:686-90.
40. 2+ current. Circ Res 1989;64:977-90.
41. Makielski JC, January CT. Proarrhythmia related to prolongation of repolarization: mechanisms, monitoring, prevention and management. Cardiac Electrophysiol Rev 1998;2: 132-5.
42. Zhou Z, Studenik C, January CT. Properties of E-4031-induced early afterdepolarizations in rabbit ventricular myocytes: studies using a perforated patch method. In: Vereecke J, van Bogaert PP, Verdonck F, eds. Potassium channels in normal and pathological conditions. Leuven: Leuven University Press, 1995:375-9.
43. Brode S, Singh BN, Anderson KP. Sotalol. Cardiac Electrophysiol Rev 1998;2:211-14.
44. Marschang H, Beyer T, Karolyi L, et al. Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide on guinea-pig papillary muscle. Cardiovasc Drugs Ther 1998;12:573-83.
45. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction (The SWORD investigators). Lancet 1996;348:7-12.
46. K activation in guinea-pig ventricular myocytes. Circ Res 1988;62:1055-8.
47. Snyders DJ, Knoth KM, Roberds SL, et al. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol 1992;41:322-30.
48. + current by almokalant in rabbit ventricular myocytes. Circ Res 1993;73:857-68.
49. Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K current by dofetilide. Circ Res 1993;72:75-83.
50. Ks) to potassium channel blockers: implications for clinical reverse use-dependent effects. J Biomed Sci 1999;6:251-9.
51. Carmeliet E. Use dependent block of the delayed K current in rabbit ventricular myocytes. Cardiovasc Drugs Ther 1993; 7:599-604.
52. Funck-Brentano C. Rate-dependence of class III actions in the heart. Fundam Clin Pharmacol 1993;7:51-9.
53. DiMarco JP, Sellers TD, Lerman BB, et al. Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J Am Coll Cardiol 1985;6:417-24.
54. Till J, Shinebourne EA, Rigby ML, et al. Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children. Br Heart J 1989;62:204-11.
55. Nishimura M, Habuchi Y, Hiromasa S, et al. Ionic basis of depressed automaticity and conduction by acetylcholine in rabbit AV node. Am J Physiol 1988;255:H7-14.
56. Belardinelli L, Giles WR, West A. Ionic mechanisms of adenosine actions in pacemaker cells from rabbit heart. J Physiol (Lond) 1988;405:615-63.
57. Wang DS, Shryock JC, Belardinelli L. Cellular basis for the negative dromotropic effect of adenosine on rabbit single atrioventricular nodal cells. Circ Res 1996;78:697-706.
58. Martynyuk AE, Kane KA, Cobbe SM, et al. Adenosine increases potassium conductance in isolated rabbit atrioventricular nodal myocytes. Cardiovasc Res 1995;30:668-75.
59. Ks function. Nat Genet 1997;17:338-40.
60. Kr potassium channel. Cell 1995;81:299-307.
61. Sanguinetti MC, Curran ME, Spector PS, et al. Spectrum of HERG K channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci USA 1996;93:2208-12.
62. Wang Q, Shen J, Li Z, et al. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet 1995;4:1603-7.
63. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80:805-11.
64. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996;12:17-23.
65. Ks potassium channel. Nature 1996;384:80-3.
66. Schott JJ, Charpentier F, Peltier S, et al. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet 1995;57:1114-22.
67. Vincent, G.M. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu Rev Med 1998;49:263-74.
68. Romano C, Gemme G, Pongiglione R. Aritime cardiache rare dell'eta pediatrica. Clin Pedriatr 1963;45:658-83.
69. Jervell A, Lange-Nielson F. Congenital deaf mutism, functional heart disease with prolongation of the QT interval and sudden death. Am Heart J 1957;54:59-68.
70. Priori SG, Barhanin J, Hauer RNW, et al. Genetic and molecular basis of cardiac arrhythmias - impact on clinical management. Eur Heart J 1999;20:174-95.
71. Bennett PB, Yazawa K, Makita N, et al. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995;376:683-5.
72. + channel linked long-QT syndrome. Circ Res 1996;78:916-24.
73. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na channel blockade and to increases in heart rate. Implications for gene specific therapy. Circulation 1995;92:3381-6.
74. Antzelevitch C. The Brugada syndrome. J Cardiovasc Electrophysiol 1998;9:513-16.
75. Grace AA. Brugada syndrome. Lancet 1999;354:445-6.
76. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391-6.
77. Chen QY, Kirsch GE, Zhang DM, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998;392:293-6.
78. Compton SJ, Lux RL, Ramsey MR, et al. Genetically denned therapy of inherited long-QT syndrome -correction of abnormal repolarization by potassium. Circulation 1996;94:1018-22.
79. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994;48:345-71.
80. van der Velden HM, van Kempen MJ, et al. Altered pattern of connexin-40 distribution in persistent atrial fibrillation in the goat. J Cardiovasc Electrophysiol 1998;9: 596-607.
81. Boyden PA, Jeck CD. Ion channel function in disease. Cardiovasc Res 1995;29:312-18.
82. Cardiac Arrhythmia Suppression Trial (CAST) investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321: 406-12.
83. CAST Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33.
84. Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-32.
85. Scherf D, Schott A. Extrasystoles and allied arrhythmias. Chicago: Yearbook Medical Publishers, 1973.
86. Mark LC, Kayden JJ, Steele JM. The physiological disposition and cardiac effects of procainamide. J Pharmacol Exp Ther 1951;102:5-15.
87. Campbell TJ. Voltage and time dependent depression of maximum rate of depolarisation of guinea pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide. Cardiovasc Res 1983;17:251-8.
88. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129-47.
89. Vaughan Williams EM. Classification of antiarrhythmic drugs. In: Sandoe E, Flenstead-Jensen E, Olesen EH, eds. Symposium on cardiac arrhythmias. Copenhagen: Astra, 1970:449-501.
90. Singh BN, Hauswirth O. Comparative mechanisms of antiarrhythmic drugs. Am Heart J 1974;87:367-82.
91. Harrison DC. Is there a rational basis for the modified classification of antiarrhythmic drugs? In: Morganroth J, Moore EN, eds. Cardiac arrhythmias: new therapeutic drugs and devices. Amsterdam: Martinus Nijhoff, 1985: 36-48.
92. Campbell TJ. Kinetics of onset of rate-dependent effects of class 1 antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res 1983;17:344-52.
93. max) in guinea pig ventricular action potentials by mexiletine, disopyramide and encainide. J Cardiovasc Pharmacol 1983;5:291-6.
94. Members of the Sicilian Gambit. The "Sicilian Gambit". A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1991;12: 1112-31.
95. Rosen MR. Consequences of the Sicilian Gambit. Eur Heart J 1995;16:G32-6.
96. Members of the Sicilian Gambit. The search for novel antiarrhythmic strategies. Eur Heart J 1998;19:1178-96.
97. Camm AJ, Yap YG. What should we expect from the next generation of antiarrhythmic drugs? J Cardiovasc Electrophysiol 1999;10:307-17.
98. Yue LX, Feng JL, Li GR, Nattel S. Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol (Lond) 1996;496: 647-62.
99. Bashir Y, Thomsen PEB, Kingma JH, et al. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Am J Cardiol 1995;76:1040-8.
100. Ferguson J. DIAMOND (Danish investigations of arrhythmia and mortality on dofetilide). Clin Cardiol 1998; 21:51-4.
101. Karam R, Marcello S, Brooks RR, et al. Azimilide dihydrochloride, a novel antiarrhythmic agent. Am J Cardiol 1998; 81:D40-6.
102. Groh WJ, Gibson KJ, Maylie JG. Comparison of the rate-dependent properties of the class III antiarrhythmic agents azimilide (NE-10064) and E-4031: consideration on the mechanism of reverse rate-dependent action potential prolongation. J Cardiovasc Electrophysiol 1997;8:529-36.
103. Gintant GA. Azimilide causes reverse rate-dependent block whilst reducing both components of the delayed rectifier current in canine ventricular myocytes. J Cardiovasc Pharmacol 1998;31:945-53.
104. Nattel S, Liu SS, StGeorges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic parameters. Cardiovasc Res 1998;37:627-35.
105. Camm AJ, Karam R, Pratt CM. The azimilide post-infarct survival evaluation (ALIVE) trial. Am J Cardiol 1998;19: 35-9D.
106. Stambler BS. Ibutilide. Cardiac Electrophysiol Rev 1998;2: 173-5.
107. Sager PT. Investigational antiarrhythmic agents. Cardiac Electrophysiol Rev 1998;2:232-5.
108. Chi L, Park JL, Friedrichs GS, et al. Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the isolated rabbit heart. Br J Pharmacol 1996;117:1261-9.
109. Bargheer K, Bode F, Klein HU, et al. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium channel blocking agent. Eur Heart J 1994;15:1409-14.